The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
β-Cell Function and the Development of Diabetes-Related Complications in the Diabetes Control and Complications Trial
Open accessAbstract
In patients with type 1 diabetes, measurement of connecting peptide (C-peptide), cosecreted with insulin from the islets of Langerhans, permits estimation of remaining β-cell secretion of insulin. In this retrospective analysis to distinguish the incremental benefits of residual β-cell activity in type 1 diabetes, stimulated (90 min following ingestion of a mixed meal) C-peptide levels at entry in the Diabetes Control and Complications Trial (DCCT) were related to measures of diabetic retinopathy and nephropathy and to incidents of severe hypoglycemia. Based on the analytical sensitivity of the assay (0.03 nmol/l) and study entry criteria, the DCCT subjects were divided into four groups of stimulated C-peptide responses: ≤0.03, 0.04–0.20, 0.21–0.50 nmol/l at entry, and 0.21–0.50 nmol/l at entry and at least 1 year later (sustained C-peptide secretion). Uniformly in the intensive and partially in the conventional DCCT treatment groups, any C-peptide secretion, but especially at higher and sustained levels of stimulated C-peptide, was associated with reduced incidences of retinopathy (both a single three-step change and a repeated three-step change on the Early Treatment of Diabetic Retinopathy Study [ETDRS] scale at the next 6 month visit) and nephropathy (both albuminuria >40 mg/24 h once and repeated at the next annual visit). There were also differences in severe hypoglycemia across C-peptide levels in both treatment groups. In the intensively treated cohort there were essentially identical prevalences of severe hypoglycemia (∼65% of participants) in the first three groups; however, those subjects with mixed-meal stimulated C-peptide level >0.20 nmol/l for at least baseline and the first annual visit in the DCCT experienced a reduced prevalence of ∼30%. Therefore, even modest levels of β-cell activity at entry in the DCCT were associated with reduced incidences of retinopathy and nephropathy. Also, continuing C-peptide (insulin) secretion is important in avoiding hypoglycemia (the major complication of intensive diabetic therapy).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Although this endogenous secretion is typically low, maintenance is important since it is associated with less retinopathy and less severe hypoglycaemia at later stages of the disease.86”
From Type 1 diabetes (2014) · cites this paper as [86]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“natural history studies, intervention trials, and transplantation studies consistently show that higher Cpeptide responses to a mixed meal are associated with improved glycaemic control, fewer hypoglycaemic episodes, and reduced longterm complications.[55][56][57]”
From The future of type 1 diabetes therapy (2025) · cites this paper as [57]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“This finding is noteworthy because in the Diabetes Control and Complications Trial68,69 persistent C-peptide secretion was associated with reduced development of retinopathy, nephropathy, and hypoglycaemia.”
From Type 1 diabetes (2018) · cites this paper as [69]
In the citing paper
“In addition, we analysed two other thresholds: UCPCR≥0.03 nmol/mmol and ≥0.2nmol/mmol, which are equivalent to serum C peptide of 30 pmol/L (a common historical limit of detection(3; 11; 12)) and 200 pmol/L (a clinically defined level associated with reduced microvascular complications and hypoglycaemia(13)).”
From Most people with long-duration type 1 diabetes in a large population-based study are insulin microsecretors (2015) · cites this paper as [11]
In the citing paper
“The strongest evidence to date, however, finds that while higher and sustained levels of C-peptide are most beneficial, even modest levels of β-cell function in some with long-term disease are associated with lower rates of hypoglycemia and lower incidence of retinopathy and nephropathy (9,11).”
From Persistence of prolonged C-peptide production in type 1 diabetes as measured with an ultrasensitive C-peptide assay (2012) · cites this paper as [11]
In the citing paper
“The strongest evidence to date, however, finds that while higher and sustained levels of C-peptide are most beneficial, even modest levels of β-cell function in some with long-term disease are associated with lower rates of hypoglycemia and lower incidence of retinopathy and nephropathy (9,11).”
From Persistence of prolonged C-peptide production in type 1 diabetes as measured with an ultrasensitive C-peptide assay (2012) · cites this paper as [11]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
Statistical Methods in Cancer Research. Volume II – The Design and Analysis of Cohort Studies
Juul, S. (1989) · Scandinavian Journal of Social Medicine · doi:10.1177/140349488901700214 · Cited by 3,602
The design and analysis of cohort studies
Breslow, N. E., & Day, N. E. (1987) · International Agency for Research on Cancer eBooks · Cited by 1,312
The Diabetes Control and Complications (DCCT) Research Group (1995) · Kidney International · doi:10.1038/ki.1995.236 · Cited by 694
Gerich, J. E., Langlois, M., Noacco, C., Karam, J. H., & Forsham, P. H. (1973) · Science · doi:10.1126/science.182.4108.171 · Cited by 688
(1998) · Annals of Internal Medicine · doi:10.7326/0003-4819-128-7-199804010-00001 · Cited by 546
The DCCT Research Group (1986) · Diabetes · doi:10.2337/diabetes.35.5.530 · Cited by 466
(1995) · Archives of Ophthalmology · doi:10.1001/archopht.1995.01100010038019 · Cited by 325
Hypoglycemia: The Limiting Factor in the Management of IDDM
Cryer, P. E. (1994) · Diabetes · doi:10.2337/diab.43.11.1378 · Cited by 307
THE DCCT RESEARCH GROUP (1987) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-65-1-30 · Cited by 215
Flagged first, then by citations
Cited by
Sorted by citations
Items 201–300 of 697
Residual C-peptide in type 1 diabetes: what do we really know?
VanBuecken, D., & Greenbaum, C. J. (2014) · Pediatric Diabetes · doi:10.1111/pedi.12135 · Cited by 43
New and future immunomodulatory therapy in type 1 diabetes
Tooley, J., Waldron-Lynch, F., & Herold, K. C. (2012) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2012.01.001 · Cited by 44
Helminen, O., Pokka, T. M.-L., Tossavainen, P. H., Ilonen, J., Knip, M., & Veijola, R. (2016) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2016.07.027 · Cited by 42
Cadario, F., Pozzi, E., Rizzollo, S., Stracuzzi, M., Beux, S., Giorgis, A., Carrera, D., Fullin, F., Riso, S., Rizzo, A. M., et al. (2019) · Nutrients · doi:10.3390/nu11092158 · Cited by 41
Targeting Memory T Cells in Type 1 Diabetes
Ehlers, M. R., & Rigby, M. R. (2015) · Current Diabetes Reports · doi:10.1007/s11892-015-0659-5 · Cited by 40
Hoffmann, L. E., Kohls, M., Arnolds, S., Achenbach, P., Bergholdt, R., Bonifacio, E. E., Bosi, E., Gündert, M., Hoefelschweiger, B. K., Hummel, S., et al. (2025) · BMJ Open · doi:10.1136/bmjopen-2024-088522 · Cited by 46
Holst, J. J., & McGill, M. A. (2011) · Clinical Drug Investigation · doi:10.2165/11595370-000000000-00000 · Cited by 40
Reddy, S. S. R., Amutha, A., Rajalakshmi, R., Regin, B., Monickaraj, F., Rangasamy, S., Anjana, R. M., Shiny, A., Gokulakrishnan, K., Das, A., et al. (2017) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2017.02.017 · Cited by 40
Lin, Y. K., Groat, D., Chan, O. T. M., Hung, M., Sharma, A. R., Varner, M. W., Gouripeddi, R., Facelli, J. C., & Fisher, S. J. (2019) · Journal of the Endocrine Society · doi:10.1210/jendso/bvz005 · Cited by 43
Schölin, A., Nyström, L., Arnqvist, H. J., Bolinder, J., Björk, E., Berne, C., Karlsson, F. A., & the Diabetes Incidence Study Group in Sweden (DISS) (2010) · Diabetic Medicine · doi:10.1111/j.1464-5491.2010.03191.x · Cited by 40
Cabrera, S. M., Colvin, S. C., Tersey, S. A., Maier, B., Nadler, J. L., & Mirmira, R. G. (2013) · Clinical & Experimental Immunology · doi:10.1111/cei.12068 · Cited by 41
Mishra, A., Dayal, D., Sachdeva, N. K., & Attri, S. V. (2015) · Journal of Pediatric Endocrinology and Metabolism · doi:10.1515/jpem-2015-0088 · Cited by 41
Narendran, P., Solomon, T. P. J., Kennedy, A., Chimen, M., & Andrews, R. C. (2014) · Diabetologia · doi:10.1007/s00125-014-3412-8 · Cited by 40
Barra, J. M., Robino, R. A., Castro-Gutiérrez, R., Proia, J., Russ, H. A., & Ferreira, L. M. R. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.114994 · Cited by 40
Dunger, D. B., Bruggraber, S. F. A., Mander, A., Marcovecchio, M. L., Tree, T. I. M., Chmura, P. J., Knip, M., Schulte, A. M., Mathieu, C., Mathieu, C., et al. (2022) · Trials · doi:10.1186/s13063-022-06259-z · Cited by 39
Jones, A. G., Besser, R. E. J., McDonald, T. J., Shields, B. M., Hope, S. V., Bowman, P., Oram, R. A., Knight, B., & Hattersley, A. T. (2011) · Diabetic Medicine · doi:10.1111/j.1464-5491.2011.03272.x · Cited by 39
Lascar, N., Kennedy, A., Jackson, N., Daley, A., Dowswell, G., Thompson, D., Stokes, K., Greenfield, S., HOLDER, R. L., Andrews, R. C., et al. (2013) · Trials · doi:10.1186/1745-6215-14-180 · Cited by 38
Pathophysiology of insulin secretion
Scheen, A. J. (2004) · Annales d Endocrinologie · doi:10.1016/s0003-4266(04)95627-2 · Cited by 38
Garavelli, S., Bruzzaniti, S., Tagliabue, E., Di Silvestre, D., Prattichizzo, F., Mozzillo, E., Fattorusso, V., La Sala, L., Ceriello, A., Puca, A. A., et al. (2020) · Diabetologia · doi:10.1007/s00125-020-05237-x · Cited by 37
Marren, S. M., Hammersley, S., McDonald, T. J., Shields, B. M., Knight, B., Hill, A., Bolt, R. F., Tree, T. I. M., Roep, B. O., Hattersley, A. T., et al. (2019) · Diabetic Medicine · doi:10.1111/dme.13960 · Cited by 38
Garavelli, S., Bruzzaniti, S., Tagliabue, E., Prattichizzo, F., Silvestre, D. D., Perna, F., Sala, L. L., Ceriello, A., Mozzillo, E., Fattorusso, V., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21020477 · Cited by 37
Ludvigsson, J. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21051598 · Cited by 37
McGee, P., Steffes, M. W., Nowicki, M., Bayless, M., Gubitosi‐Klug, R., Cleary, P. A., Lachin, J. M., & Palmer, J. P. (2014) · Diabetic Medicine · doi:10.1111/dme.12504 · Cited by 37
Self-citationIslet Versus Pancreas Transplantation in Type 1 Diabetes: Competitive or Complementary?
Ludwig, B., Ludwig, S., Steffen, A., Saeger, H., & Bornstein, S. R. (2010) · Current Diabetes Reports · doi:10.1007/s11892-010-0146-y · Cited by 38
and The VADT Study Group, Azad, N., Agrawal, L., Emanuele, N., Klein, R., Bahn, G., & Reaven, P. D. (2014) · Diabetologia · doi:10.1007/s00125-014-3199-7 · Cited by 36
Wherrett, D. K., & Daneman, D. (2009) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2009.08.006 · Cited by 36
Petrone, A., Spoletini, M., Zampetti, S., Capizzi, M., Zavarella, S., Osborn, J., Pozzilli, P., Buzzetti, R., & for the Immunotherapy Diabetes (IMDIAB) Group (2008) · Diabetes Care · doi:10.2337/dc07-1158 · Cited by 36
Sirtuin 6, a possible therapeutic target for type 2 diabetes
Bae, E. J. (2017) · Archives of Pharmacal Research · doi:10.1007/s12272-017-0989-8 · Cited by 36
Interventions for latent autoimmune diabetes (LADA) in adults
Brophy, S. T., Brunt, H., Davies, H. A., Mannan, S., & Williams, R. (2007) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006165.pub2 · Cited by 36
Lamichhane, A. P., Crandell, J., Jaacks, L. M., Couch, S. C., Lawrence, J. M., & Mayer‐Davis, E. J. (2015) · American Journal of Clinical Nutrition · doi:10.3945/ajcn.114.103747 · Cited by 35
Beta cell function during rapamycin monotherapy in long-term type 1 diabetes
Piemonti, L., Maffi, P., Monti, L., Lampasona, V., Perseghin, G., Magistretti, P., Secchi, A., & Bonifacio, E. E. (2010) · Diabetologia · doi:10.1007/s00125-010-1959-6 · Cited by 36
Michels, A. W., & von Herrath, M. (2011) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0b013e32834803ae · Cited by 35
Rachmiel, M., Strauss, P., Dror, N., Benzaquen, H., Horesh, O., Tov, N., Weintrob, N., Landau, Z., Ben‐Ami, M., Haim, A., et al. (2015) · Pediatric Diabetes · doi:10.1111/pedi.12283 · Cited by 35
Barra, J. M., Kozlovskaya, V., Kharlampieva, E., Tse, H. M., & Tse, H. M. (2020) · Diabetes · doi:10.2337/db20-0248 · Cited by 35
Baek, J. H., Lee, W. J., Lee, B., Kim, S. Y., Kim, G., Jin, S., & Kim, J. H. (2020) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2019.0134 · Cited by 36
Type 1 Diabetes TrialNet CTLA4-Ig (Abatacept) Study Group, Cabrera, S. M., Engle, S., Kaldunski, M. L., Jia, S., Geoffrey, R., Simpson, P. M., Szabó, A., Speake, C., Greenbaum, C. J., et al. (2018) · Diabetologia · doi:10.1007/s00125-018-4708-x · Cited by 35
Time for Testing Incretin Therapies in Early Type 1 Diabetes?
Bosi, E. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-2741 · Cited by 34
Landstra, C. P., Andrès, A., Chetboun, M., Conte, C., Kelly, Y. M., Berney, T., de Koning, E. J. P., Piemonti, L., Stock, P. G., Pattou, F. N., et al. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab386 · Cited by 35
Zhu, S., Lu, Y., Zhu, J., Xu, J., Huang, H., Zhu, M., Chen, Y., Zhou, Y., Fan, X., & Wang, Z. (2009) · Journal of Surgical Research · doi:10.1016/j.jss.2009.10.008 · Cited by 35
Roshandel, D., Gubitosi‐Klug, R., Bull, S. B., Canty, A. J., Pezzolesi, M. G., King, G. L., Keenan, H. A., Snell‐Bergeon, J. K., Maahs, D. M., Klein, R., et al. (2018) · Diabetologia · doi:10.1007/s00125-018-4555-9 · Cited by 33
Zhao, L., Ma, J., Wang, S., & Xie, Y. (2015) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2014.0214 · Cited by 32
Fischer, B., Elias, D., Bretzel, R. G., & Linn, T. (2009) · Expert Opinion on Biological Therapy · doi:10.1517/14712590903555176 · Cited by 32
Intralymphatic GAD-Alum (Diamyd®) Improves Glycemic Control in Type 1 Diabetes With HLA DR3-DQ2
Nowak, C., Lind, M., Šumník, Z., Pelikánová, T., Nattero‐Chávez, L., Lundberg, E., Rica, I., Martínez‐Brocca, M. A., de Adana, M. R., Wahlberg, J., et al. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac343 · Cited by 33
Genetic Engineering of Immune Evasive Stem Cell-Derived Islets
Sackett, S. D., Kaplan, S. J., Mitchell, S. A., Brown, M. E., Burrack, A. L., Grey, S., Huangfu, D., & Odorico, J. (2022) · Transplant International · doi:10.3389/ti.2022.10817 · Cited by 32
Kordonouri, O., Hartmann, R., Pańkowska, E., Rami-Merhar, B. M., Kapellen, T. M., Coutant, R., Lange, K., & Danne, T. (2012) · Pediatric Diabetes · doi:10.1111/j.1399-5448.2012.00863.x · Cited by 32
Spontaneous complete remission of type 1 diabetes mellitus in an adult – review and case report
Moole, H. V., Moole, V., Mamidipalli, A., Dharmapuri, S., Boddireddy, R. R., Taneja, D., Sfeir, H., & Gajula, S. (2015) · Journal of Community Hospital Internal Medicine Perspectives · doi:10.3402/jchimp.v5.28709 · Cited by 32
Jensen, R. A., Agardh, E., Lernmark, Å., Guðbjörnsdóttir, S., Smith, N. L., Siscovick, D. S., Törn, C., & on behalf of the DISS Group (2011) · PLoS ONE · doi:10.1371/journal.pone.0017569 · Cited by 32
Waldron-Lynch, F., Kareclas, P., Kathryn, I., Walker, N. M., Mander, A., Wicker, L. S., Todd, J. A., & Bond, S. J. (2014) · BMJ Open · doi:10.1136/bmjopen-2014-005559 · Cited by 31
Gluten‐free diet in children with recent‐onset type 1 diabetes: A 12‐month intervention trial
Neuman, V., Průhová, Š., Kulich, M., Koloušková, S., Vosáhlo, J., Romanová, M., Petruželková, L., Obermannová, B., Funda, D. P., Cinek, O., et al. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13974 · Cited by 32
State of the art paper Influence of lifestyle on the course of type 1 diabetes mellitus
Piłaciński, S., & Zozulińska‐Ziółkiewicz, D. (2014) · Archives of Medical Science · doi:10.5114/aoms.2014.40739 · Cited by 32
Nwosu, B. U. (2019) · European Medical Journal · doi:10.33590/emj/10310168 · Cited by 31
Autologous Hematopoietic Stem Cell Transplantation for Childhood Autoimmune Disease
Milanetti, F., Abinun, M., Voltarelli, J. C., & Burt, R. K. (2010) · Pediatric Clinics of North America · doi:10.1016/j.pcl.2009.12.003 · Cited by 30
miRNA-Mediated Immune Regulation in Islet Autoimmunity and Type 1 Diabetes
Scherm, M. G., & Daniel, C. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.606322 · Cited by 30
Insulin micro-secretion in Type 1 diabetes and related microRNA profiles
Januszewski, A. S., Cho, Y. H., Joglekar, M. V., Farr, R. J., SCOTT, E. S., Wong, W. K. M., Carroll, L. M., Loh, Y. W., Benitez‐Aguirre, P., KEECH, A. C., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-90856-6 · Cited by 32
Wake, A. D. (2022) · World Journal of Diabetes · doi:10.4239/wjd.v13.i3.161 · Cited by 36
Dejgaard, T. F., Frandsen, C. S., Kielgast, U., Størling, J., Overgaard, A. J., Svane, M. S., Olsen, M. H., Thorsteinsson, B., Andersen, H. U., Krarup, T., et al. (2024) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15889 · Cited by 29
Autoimmunity in gestational diabetes mellitus in Sardinia: a preliminary case-control report
Murgia, C., Orrù, M., Portoghese, E., Garau, N., Zedda, P., Berria, R., Motzo, C., Sulis, S., Murenu, M., Paoletti, A. M., et al. (2008) · Reproductive Biology and Endocrinology · doi:10.1186/1477-7827-6-24 · Cited by 29
Lundberg, R. L., Marino, K. R., Jasrotia, A., Maranda, L., BARTON, B. A., Alonso, L. C., & Nwosu, B. U. (2017) · Journal of Pediatric Endocrinology and Metabolism · doi:10.1515/jpem-2017-0019 · Cited by 30
Zenz, S., Mader, J. K., Regittnig, W., Brunner, M., Korsatko, S., Boulgaropoulos, B., Magnes, C., Raml, R., Narath, S. H., Eller, P., et al. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2017-01836 · Cited by 29
Brill, A. L., Wisinski, J. A., Cadena, M. T., Thompson, M. F., Fenske, R. J., Brar, H. K., Schaid, M. D., Pasker, R. L., & Kimple, M. E. (2016) · Molecular Endocrinology · doi:10.1210/me.2015-1164 · Cited by 28
Progress and challenges for treating Type 1 diabetes
Garyu, J., Meffre, E., Cotsapas, C. J., & Herold, K. C. (2016) · Journal of Autoimmunity · doi:10.1016/j.jaut.2016.04.004 · Cited by 30
Redox-Dependent Inflammation in Islet Transplantation Rejection
Barra, J. M., & Tse, H. M. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00175 · Cited by 29
Pinheiro, M. M., Pinheiro, F. M. M., Diniz, S. N., Fabbri, A., & Infante, M. (2021) · International Immunopharmacology · doi:10.1016/j.intimp.2021.107518 · Cited by 28
Zhang, S., Deng, F., Chen, J., Chen, F., Wu, Z., Li, L., & Hou, K. (2022) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2022.1075201 · Cited by 30
Yoon, H., Cho, Y.-Z., Kim, J., Kim, B.-J., Park, K., Koh, G., Lee, D.-H., & Lim, D.-M. (2012) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2012.36.5.379 · Cited by 28
The Role of Immunomodulation Therapy in Autoimmune Diabetes
Ludvigsson, J. (2009) · Journal of Diabetes Science and Technology · doi:10.1177/193229680900300213 · Cited by 28
Hals, I. K., Fleiner, H. F., Reimers, N., Astor, M. C., Filipsson, K., Ma, Z., Grill, V., & Björklund, A. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13797 · Cited by 28
Therapies to Preserve β-Cell Function in Type 1 Diabetes
Ludvigsson, J. (2015) · Drugs · doi:10.1007/s40265-015-0511-x · Cited by 29
Islet Cell Transplantion: Update on Current Clinical Trials
Schuetz, C., & Markmann, J. F. (2016) · Current Transplantation Reports · doi:10.1007/s40472-016-0103-z · Cited by 30
Age at Diagnosis and C-Peptide Level Are Associated with Diabetic Retinopathy in Chinese
Cai, X., Han, X., Zhang, S., Luo, Y., Chen, Y., & Ji, L. (2014) · PLoS ONE · doi:10.1371/journal.pone.0091174 · Cited by 27
Treatment of new onset type 1 diabetes with teplizumab: successes and pitfalls in development
Vudattu, N. K., & Herold, K. C. (2014) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2014.881797 · Cited by 28
Chen, Y.-C., Tung, Y., Liu, S., Lee, C.-T., & Tsai, W. (2016) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2016.07.005 · Cited by 27
Residual β-Cell Mass Influences Growth of Prepubertal Children With Type 1 Diabetes
Bizzarri, C., Benevento, D., Patera, I. P., Bongiovanni, M., Boiani, A., Fusco, C., Cianfarani, S., & Cappa, M. (2013) · Hormone Research in Paediatrics · doi:10.1159/000355116 · Cited by 29
New potential treatments for protection of pancreatic B‐cell function in Type 1 diabetes
Cernea, S., & Pozzilli, P. (2008) · Diabetic Medicine · doi:10.1111/j.1464-5491.2008.02556.x · Cited by 27
Latent autoimmune diabetes in adults
Gilliam, L. K., & Palmer, J. P. (2006) · Insulin · doi:10.1016/s1557-0843(06)80021-7 · Cited by 27
Chinnakotla, S., Beilman, G. J., Vock, D. M., Freeman, M. L., Kirchner, V. A., Dunn, T. B., Pruett, T. L., Amateau, S. K., Trikudanathan, G., Schwarzenberg, S. J., et al. (2022) · Annals of Surgery · doi:10.1097/sla.0000000000005553 · Cited by 26
Monitoring Inflammation, Humoral and Cell-mediated Immunity in Pancreas and Islet Transplants
Monti, P., Vignali, D., & Piemonti, L. (2015) · Current Diabetes Reviews · doi:10.2174/1573399811666150317125820 · Cited by 27
miRNA Regulation of T Cells in Islet Autoimmunity and Type 1 Diabetes
Scherm, M. G., & Daniel, C. (2020) · Current Diabetes Reports · doi:10.1007/s11892-020-01325-9 · Cited by 27
Jiang, Z., Ren, W., Liang, H., Yan, J., Yang, D., Luo, S., Zheng, X., Lin, G.-W., Xian, Y., Xu, W., et al. (2021) · Diabetologia · doi:10.1007/s00125-021-05476-6 · Cited by 26
Belgian Diabetes Registry, Dalem, A. V., Demeester, S., Balti, E. V., Decochez, K., Weets, I., Vandemeulebroucke, E., de Velde, U. V., Walgraeve, A., Seret, N., et al. (2015) · Diabetologia · doi:10.1007/s00125-015-3761-y · Cited by 26
Immune interventions to preserve β cell function in type 1 diabetes
Ehlers, M. R. (2015) · Journal of Investigative Medicine · doi:10.1097/jim.0000000000000227 · Cited by 28
Pinckney, A., Rigby, M. R., Keyes-Elstein, L., Soppe, C. L., Nepom, G. T., & Ehlers, M. R. (2016) · Clinical Therapeutics · doi:10.1016/j.clinthera.2016.04.032 · Cited by 26
Nwosu, B. U., Zhang, B., Ayyoub, S., Choi, S. H., Villalobos-Ortiz, T. R., Alonso, L. C., & BARTON, B. A. (2018) · PLoS ONE · doi:10.1371/journal.pone.0196912 · Cited by 26
Chetan, M. R., Charlton, M., Thompson, C., Dias, R. P., Andrews, R. C., & Narendran, P. (2018) · Diabetic Medicine · doi:10.1111/dme.13802 · Cited by 26
Marcovecchio, M. L., Wicker, L. S., Dunger, D. B., Dutton, S., Kopijasz, S., Scudder, C. L., Todd, J. A., & Johnson, P. R. V. (2020) · Wellcome Open Research · doi:10.12688/wellcomeopenres.15697.1 · Cited by 26
CD4+CD25+CD127hi cell frequency predicts disease progression in type 1 diabetes
Narsale, A. A., Lam, B., Moya, R., Lü, T., Mandelli, A., Gotuzzo, I., Pessina, B., Giamporcaro, G. M., Geoffrey, R., Buchanan, K., et al. (2020) · JCI Insight · doi:10.1172/jci.insight.136114 · Cited by 26
Pancreatic islet reserve in type 1 diabetes
Flatt, A. J., Greenbaum, C. J., Shaw, J., & Rickels, M. R. (2021) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.14572 · Cited by 27
Heterogeneity in recent‐onset type 1 diabetes – a clinical trial perspective
Bollyky, J., Xu, P., Butte, A. J., Wilson, D. M., Beam, C. A., Greenbaum, C. J., & Type 1 Diabetes TrialNet Study Group (2015) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2643 · Cited by 25
The Belgian Diabetes Registry, Vandemeulebroucke, E., Keymeulen, B., Decochez, K., Weets, I., Block, C. E. M. D., Féry, F., de Velde, U. V., Vermeulen, I., Pauw, P. E. M. D., et al. (2009) · Diabetologia · doi:10.1007/s00125-009-1569-3 · Cited by 27
Kuo, J. Z.-C., Guo, X., Klein, R., Klein, B. E. K., Weinreb, R. N., Genter, P. M., Hsiao, F., Goodarzi, M. O., Rotter, J. I., Chen, Y.-D. I., et al. (2014) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2014-000027 · Cited by 25
Chung, J. O., Cho, D. H., Chung, D. J., & Chung, M. Y. (2014) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2014.12.013 · Cited by 25
Role of C‐Peptide in the Regulation of Microvascular Blood Flow
Forst, T. M., Kunt, T., Wilhelm, B., Weber, M. M., & Pfützner, A. (2008) · Journal of Diabetes Research · doi:10.1155/2008/176245 · Cited by 25
Total Pancreatectomy With Islet Autotransplantation for Acute Recurrent and Chronic Pancreatitis
Kirchner, V. A., Dunn, T. B., Beilman, G. J., Chinnakotla, S., Pruett, T. L., Wilhelm, J. J., Schwarzenberg, S. J., Freeman, M. L., & Bellin, M. D. (2017) · Current Treatment Options in Gastroenterology · doi:10.1007/s11938-017-0148-9 · Cited by 25
C-peptide and residual β-cell function in pediatric diabetes – state of the art
Jamiołkowska‐Sztabkowska, M., Głowińska‐Olszewska, B., & Bossowski, A. T. (2021) · Pediatric Endocrinology Diabetes and Metabolism · doi:10.5114/pedm.2021.107165 · Cited by 26
Immune Monitoring of Islet and Pancreas Transplant Recipients
Abreu, J., & Roep, B. O. (2013) · Current Diabetes Reports · doi:10.1007/s11892-013-0399-3 · Cited by 26
Strategies for clinical trials in type 1 diabetes
Ehlers, M. R. (2016) · Journal of Autoimmunity · doi:10.1016/j.jaut.2016.03.008 · Cited by 25
Diabetes technology and treatments in the paediatric age group
Shalitin, S., & Chase, H. P. (2011) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2010.02582.x · Cited by 24
Immune Intervention in Type I Diabetes Mellitus
Ludvigsson, J. (2013) · InTech eBooks · doi:10.5772/52801 · Cited by 24
Immune intervention at diagnosis ? should we treat children to preserve beta-cell function?
Ludvigsson, J. (2007) · Pediatric Diabetes · doi:10.1111/j.1399-5448.2007.00299.x · Cited by 24
Zeynaloo, E., Stone, L. D., Dikici, E., Ricordi, C., Deo, S. K., Bachas, L. G., Daunert, S., & Lanzoni, G. (2021) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2021.101063 · Cited by 23
Metadata
- Authors
- Steffes, M. W., Sibley, S., Jackson, M., & Thomas, W.
- Affiliations
- University of Minnesota (US)
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2003-03-01
- Volume
- 26
- Issue
- 3
- Pages
- 832-836
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W1988519907
- Cited by
- 695
- References
- 25
- Citations by year
- 2026: 20 · 2025: 26 · 2024: 30 · 2023: 34 · 2022: 39 · 2021: 49 · 2020: 38 · 2019: 29 · 2018: 31 · 2017: 32 · 2016: 30 · 2015: 44 · 2014: 32 · 2013: 53 · 2012: 37
- FWCI
- 8.55
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Center for Research Resources (M01RR000400, M01-RR00400)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Diabetes and associated disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Keywords
- type 1 diabetes, residual beta-cell function, C-peptide, diabetic retinopathy, diabetic nephropathy, albuminuria, severe hypoglycemia, intensive insulin therapy, diabetes complications, Diabetes Control and Complications Trial
- MeSH terms
- Adult, Blood Glucose, C-Peptide, Diabetes Mellitus, Type 1, Diabetic Nephropathies, Diabetic Retinopathy, Female, Glycated Hemoglobin, Humans, Hypoglycemia, Islets of Langerhans, Male, Retrospective Studies
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
